Brief: Nuvectis Pharma Announces Positive Data For Nxp900 In A Preclinical Model Of Group 4 Medulloblastoma, A Type Of Brain Cancer That Affects Predominantly Pediatric Patients
13/06/2022 13:33
June 13 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES POSITIVE DATA FOR NXP900 IN A
PRECLINICAL MODEL OF GROUP 4 MEDULLOBLASTOMA, A TYPE OF BRAIN
CANCER THAT AFFECTS PREDOMINANTLY PEDIATRIC PATIENTS
Source text for Eikon: ID:nGNX9Kv6k9
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin